Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study

Ralf W. Dittmann; Esther Cardo; Peter Nagy; Colleen S. Anderson; Ralph Bloomfield; Beatriz Caballero; Nicholas Higgins; Paul Hodgkins; Andrew Lyne; Richard Civil; David Coghill

doi:10.1007/s40263-013-0104-8

Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study

Ralf W. Dittmann (Lead / Corresponding author), Esther Cardo, Peter Nagy, Colleen S. Anderson, Ralph Bloomfield, Beatriz Caballero, Nicholas Higgins, Paul Hodgkins, Andrew Lyne, Richard Civil, David Coghill

Research output: Contribution to journal › Article › peer-review

72 Citations (Scopus)

Abstract

The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).

Original language	English
Article number	n/a
Number of pages	12
Journal	CNS Drugs
Volume	n/a
DOIs	https://doi.org/10.1007/s40263-013-0104-8
Publication status	Published - 20 Aug 2013

Access to Document

10.1007/s40263-013-0104-8

Cite this

Dittmann, R. W., Cardo, E., Nagy, P., Anderson, C. S., Bloomfield, R., Caballero, B., Higgins, N., Hodgkins, P., Lyne, A., Civil, R., & Coghill, D. (2013). Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs, n/a, Article n/a. https://doi.org/10.1007/s40263-013-0104-8

@article{693a190ce637428ba2818dcaa6b59138,

title = "Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study",

abstract = "The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).",

author = "Dittmann, {Ralf W.} and Esther Cardo and Peter Nagy and Anderson, {Colleen S.} and Ralph Bloomfield and Beatriz Caballero and Nicholas Higgins and Paul Hodgkins and Andrew Lyne and Richard Civil and David Coghill",

year = "2013",

month = aug,

day = "20",

doi = "10.1007/s40263-013-0104-8",

language = "English",

volume = "n/a",

journal = "CNS Drugs",

issn = "1179-1934",

publisher = "Springer Verlag",

}

Dittmann, RW, Cardo, E, Nagy, P, Anderson, CS, Bloomfield, R, Caballero, B, Higgins, N, Hodgkins, P, Lyne, A, Civil, R & Coghill, D 2013, 'Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study', CNS Drugs, vol. n/a, n/a. https://doi.org/10.1007/s40263-013-0104-8

Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. / Dittmann, Ralf W. (Lead / Corresponding author); Cardo, Esther; Nagy, Peter et al.
In: CNS Drugs, Vol. n/a, n/a, 20.08.2013.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder

T2 - a head-to-head, randomized, double-blind, phase IIIb study

AU - Dittmann, Ralf W.

AU - Cardo, Esther

AU - Nagy, Peter

AU - Anderson, Colleen S.

AU - Bloomfield, Ralph

AU - Caballero, Beatriz

AU - Higgins, Nicholas

AU - Hodgkins, Paul

AU - Lyne, Andrew

AU - Civil, Richard

AU - Coghill, David

PY - 2013/8/20

Y1 - 2013/8/20

N2 - The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).

AB - The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).

U2 - 10.1007/s40263-013-0104-8

DO - 10.1007/s40263-013-0104-8

M3 - Article

C2 - 23959815

SN - 1179-1934

VL - n/a

JO - CNS Drugs

JF - CNS Drugs

M1 - n/a

ER -

Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study

Abstract

Access to Document

Fingerprint

Cite this